News
12-03-2008, 10:20 AM
Findings published in the December 1, 2008, issue of Clinical Cancer Research , a journal of the American Association for Cancer Research, show lapatinib benefits women with HER2-positive breast cancer, while women with HER2-negative breast cancer or those who express EGRF alone derive no incremental benefit.
More... (http://www.medicalnewstoday.com/articles/131645.php)
More... (http://www.medicalnewstoday.com/articles/131645.php)